Advertisement
Organisation › Details
Medicxi III fund
In July 2019 Medicxi announces the closing of Medicxi III, a new €400 million fund. This brings the total amount raised by Medicxi in the last three years to over $1 billion. From this single fund, Medicxi will invest in early and late stage biopharma companies across the full healthcare continuum from discovery to late stage clinical assets. Cornerstone strategic investors in Medicxi III are Novartis and Johnson & Johnson Innovation - JJDC, Inc. (JJDC), both of whom have backed Medicxi in earlier funds. The fund also includes all of the institutional limited partners that previously invested in Medicxi's funds, as well as several new investors, including established hospital foundations and medical institutions. Medicxi III will be supported by the Medicxi Scientific Advisory Board, which benefits from the scientific and commercial expertise of senior executives from Novartis, the Janssen Pharmaceutical Companies of Johnson & Johnson, GlaxoSmithKline and Verily (an Alphabet company). The new fund will continue to focus on Medicxi's pioneering 'asset-centric' investment model as well as investing in fully integrated private companies with an underlying platform and/or a pipeline of assets that Medicxi believes can deliver licensed pharmaceutical products to satisfy unmet medical needs. The size of the fund and the speed with which it was closed reflects the continued maturity of the life sciences sector across Europe, with investors now prioritizing their attention and support for emerging biopharma companies and their efforts to translate breakthrough science into pipelines of new drugs. *
Start | 2019-07-19 closing | |
Group | Medicxi Ventures (formerly Index Ventures Life Sciences) | |
Industry | Medicxi III fund | |
Industry 2 | LIFE SCIENCES | |
Person | de Rubertis, Francesco (Medecxi Ventures 201602 General Partner before Index Ventures 200708 General Partner) | |
Region | London, Greater London | |
Country | United Kingdom (GB) | |
Street | 3 Burlington Gardens | |
City | W1S 3EP London | |
Tel | +44-20-7154-2020 | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: Medicxi Ventures. (7/19/19). "Press Release: Medicxi Closes a New €400m Fund (Medicxi III) to Power the Next Wave of Biopharma Entrepreneurs and Drug Hunters". London, Geneva & Jersey. | ||
Record changed: 2020-08-04 |
Advertisement
More documents for Medicxi Ventures (formerly Index Ventures Life Sciences)
- [1] Aldena Therapeutics Inc.. (3/16/23). "Press Release: Aldena Therapeutics Accelerates Its Novel and Disruptive Approach to Immuno-Dermatology". Boston, MA....
- [2] MiroBio Ltd.. (6/29/22). "Press Release: MiroBio Raises $97 Million Series B Financing to Develop Checkpoint Agonists for Treatment of Autoimmune Diseases". Oxford....
- [3] Centessa Pharmaceuticals Ltd.. (2/16/21). "Press Release: Centessa Pharmaceuticals Launches with $250 Million Series A Financing and Unveils a New Kind of Pharmaceutical R&D Model". Cambridge, MA & London....
- [4] Medicxi Ventures. (9/22/20). "Press Release: Medicxi Announces the Closing of Its First €200 Million Secondary Fund, Led by Pantheon with Co-lead LGT Capital Partners". London, Geneva & Jersey....
- [5] Alderaan Biotechnology SAS. (1/9/20). "Press Release: Alderaan Biotechnology Raises €18.5m in Series A from Advent France Biotechnology (AFB) and Medicxi". Paris....
- [6] Divide & Conquer. (9/18/19). "Press Release: Divide & Conquer, Developing New Class of Cancer Therapeutics to Disrupt Cell-to-Cell Communication, Emerges from Stealth as New Paper by Co-Founder is Published in Nature". Cambridge....
- [7] Medicxi Ventures. (7/19/19). "Press Release: Medicxi Closes a New €400m Fund (Medicxi III) to Power the Next Wave of Biopharma Entrepreneurs and Drug Hunters". London, Geneva & Jersey....
- [8] Sosei Group Corporation (d/b/a Sosei Heptares). (2/4/19). "Press Release: Sosei Heptares Announces Medicxi to Invest up to €40 Million in New Collaboration Based on Its Orexin Agonist Program". Tokyo & London....
- [9] Avacta Group plc. (2/4/19). "Press Release: Moderna Exercises Option for an Exclusive Product License"....
- [10] Morphogen-IX Ltd.. (12/20/18). "Press Release: Morphogen-IX Raises £18.4M ($23.2M) in a Series B Financing". Cambridge....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top